Evercore ISI Increases Danaher (NYSE:DHR) Price Target to $278.00

Danaher (NYSE:DHR) had its price target boosted by analysts at Evercore ISI from $275.00 to $278.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the conglomerate’s stock. Evercore ISI’s target price suggests a potential upside of 1.35% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Robert W. Baird raised their price objective on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Wells Fargo & Company assumed coverage on Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective on the stock. Bank of America raised their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen lifted their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Finally, Stephens started coverage on Danaher in a research note on Tuesday. They issued an “overweight” rating and a $315.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.

Danaher Stock Performance

NYSE:DHR traded down $3.72 during mid-day trading on Tuesday, hitting $274.30. 485,040 shares of the stock were exchanged, compared to its average volume of 2,779,879. The stock has a market capitalization of $203.17 billion, a price-to-earnings ratio of 46.46, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83. The firm’s 50-day simple moving average is $270.77 and its 200 day simple moving average is $258.06. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm posted $2.05 EPS. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher will post 7.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DHR. Tsfg LLC lifted its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the 2nd quarter worth approximately $25,000. nVerses Capital LLC acquired a new position in Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new position in Danaher during the 1st quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. acquired a new position in Danaher during the 4th quarter worth approximately $42,000. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.